According to CRI’s market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price. After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.9% in 2020 and reached CNY335.89 million in 2021. The CAGR of infliximab’s sales value in China is approximately 19.0% from 2017 to 2021.

According to CRI’s market research and expert interviews, CRI sees different trends in 2022 and from 2023 to 2026 in China’s infliximab market.

Sales volume and value of infliximab in China are expected to decline in 2022 as the Chinese government implements a strict “COVID-19 dynamic zeroing” policy that will prevent many healthcare facilities in China from operating normally. It is expected that the Chinese government will relax the COVID-19 control policy from early 2023 onwards, and thus the sales volume and sales value of infliximab in China will show a recovery growth from 2023-2026.

Topics Covered:

• The impact of COVID-19 on China’s Infliximab market
• Sales value of China’s Infliximab 2017-2021
• Competitive landscape of China’s Infliximab market
• Prices of Infliximab in China
• Prices of Infliximab in China by regions and manufacturers
• Analysis on factors affecting the development of China’s Infliximab market
• Prospect of China’s Infliximab market from 2022 to 2026

The post Investigation Report on China’s Infliximab Market 2022-2031 first appeared on CRI Report.

According to CRI’s market research, since Pertuzumab entered the Chinese market, the sales grew rapidly, from CNY21.15 million in 2019 to CNY501.69 million in 2020. The annual growth rate of Pertuzumab’s sales is 2272.15%.

CRI expects that based on the price reduction of Pertuzumab, its sales volume will continue to grow from 2021 to 2025. Pertuzumab was included in the medical insurance reimbursement catalog at the beginning of 2020, and the price of each 0.42g dose reduced from CNY18,800 to CNY4955. This price is valid until the end of 2021. The price of Pertuzumab is expected to be lowered again in the future. The price reduction will reduce the burden on patients, thereby increasing the usage rate of Pertuzumab and its sales. At the same time, the huge patient population will also enable the Pertuzumab market to continue to expand. Breast cancer is one of the top ten new cancer cases in China in 2020, reaching 420,000. Among them, HER2-positive patients accounted for 20%-30%. A large number of patients has also increased the demand for Pertuzumab. In addition, the effectiveness of the combination therapy of Pertuzumab and Trastuzumab has also laid down its potential in the market.

Topics Covered:
-The impact of COVID-19 on China’s Pertuzumab market
– Sales value of China’s Pertuzumab 2016-2020
– Competitive landscape of China’s Pertuzumab market
– Prices of Pertuzumab in China
– Prices of Pertuzumab in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Pertuzumab market
– Prospect of China’s Pertuzumab market from 2021 to 2025

The post Investigation Report on China’s Pertuzumab Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, since Daratumumab entered the Chinese market in 2019, its sales have grown rapidly. The sales of Daratumumab increased from around CNY0.5 million in 2019 to around CNY24.82 million in 2020, with an annual increase of more than 40 times.

CRI predicts its sales volume will continue to grow from 2021 to 2025 with the expansion of the Daratumumab market. In 2020, Johnson & Johnson has submitted two applications for the approval of Daratumumab in China for new indications. With the increase in the number of indications, its sales volume will continue to grow. In addition, Daratumumab, a novel human monoclonal antibody, binding CD38, is more effective than bortezomib and lenalidomide. Therefore, the market share of Daratumumab will expand, and sales will continue to rise in the future.

Topics Covered:
-The impact of COVID-19 on China’s Daratumumab market
– Sales value of China’s Daratumumab 2016-2020
– Competitive landscape of China’s Daratumumab market
– Prices of Daratumumab in China
– Prices of Daratumumab in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Daratumumab market
– Prospect of China’s Daratumumab market from 2021 to 2025

The post Investigation Report on China’s Daratumumab Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, Omalizumab sales have increased year by year from 2018 to 2020. At the beginning of 2020, Omalizumab was included in China’s medical insurance as a treatment for respiratory diseases. During the period of the COVID-19 epidemic, the sales of Omalizumab has increased. Therefore, its sales value reached CNY41.61 million in China in 2020, with an annual growth rate of 281.5%. The CAGR of Omalizumab’s sales value in the Chinese market from 2018 to 2020 is 163.2%.

CRI predicts that with the increase in the number of indications, the sales of Omalizumab in China will continue to grow from 2021 to 2025. China is one of the countries with the highest mortality rate of asthma in the world. In 2020, there were about 30 million asthma patients in China, which was 1.5 times higher than the number of patients in 2017 (20 million). Therefore, it can be speculated that the number of indications of Omalizumab in China will continue to grow and sales will increase accordingly. Omalizumab is clinically more accurate and more effective than inhaled corticosteroids and long-acting inhaled β2-adrenergic receptor agonists, especially for patients with moderate to severe asthma. Based on these therapeutic advantages, the market share of Omalizumab will increase in the future. In addition, Omalizumab has only been approved for one indication in China, and 4 indications have been approved globally. Therefore, the number of approved indications for Omalizumab in China still has potential for growth. It can be predicted that its sales will continue to grow with the expansion of the market and the increase of the number of indications in the future.

Topics Covered:
-The impact of COVID-19 on China’s Omalizumab market
– Sales value of China’s Omalizumab 2016-2020
– Competitive landscape of China’s Omalizumab market
– Prices of Omalizumab in China
– Prices of Omalizumab in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Omalizumab market
– Prospect of China’s Omalizumab market from 2021 to 2025

The post Investigation Report on China’s Omalizumab Market 2021-2025 first appeared on CRI Report.

Golimumab is an immunosuppressive medication that can effectively regulate inflammation and bone metabolism. The trade name of Golimumab is SIMPONI, which was developed by Janssen Biologics BV. Its products were launched in China for the treatment of ankylosing spondylitis（AS）and rheumatoid arthritis (RA) in 2018. As of the first half of 2021, Janssen Biologics BV is the only manufacturer in the Chinese Golimumab market.

According to CRI’s market research, the sales of Golimumab in the Chinese market have had a rapid upward trend from 2018 to 2020. The annual sales revenue in 2020 is CNY6.32 million, which increased over 10 times compared to that in 2018. The CAGR of Golimumab sales in the Chinese market in 2018-2020 is 242.6%. The main reason for the rapid growth is that Golimumab was included in China’s medical insurance in 2019 and it entered the national medical insurance category B list in the field of rheumatism.

CRI analyzes that from 2021 to 2025，the sales will continue to increase due to its superior efficacy and low injection frequency. In addition, Golimumab will have a very broad market and the penetration rate of SIMPONI can be improved in the future. Therefore, the market share of Golimumab has the potential to increase, which will lead the sales volume to grow in the future.

Topics Covered:
-The impact of COVID-19 on China’s Golimumab market
– Sales value of China’s Golimumab 2016-2020
– Competitive landscape of China’s Golimumab market
– Prices of Golimumab in China
– Prices of Golimumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Golimumab market
– Prospect of China’s Golimumab market from 2021 to 2025

The post Investigation Report on China’s Golimumab Market 2021-2025 first appeared on CRI Report.

CRI’s market research shows that the sales of Tocilizumab have had an increasing trend from 2016 to 2020. Since Tocilizumab was approved for the new indication sJIA in 2016, the sales increase in 2017 with 21.30% of the growth rate from 2016 to 2017. With the inclusion of Tocilizumab in China’s medical insurance in 2019 and the approval of its new indications in China in 2020, the sales in 2020 increased evidently, from CNY20.07million in 2019 to CNY41.72 million in 2020. The growth rate is about 107.89%. The CAGR of Tocilizumab was 16.25% from 2016 to 2020.
According to CRI’s market research, as the Tocilizumab market will expand from 2021 to 2025, its sales will continue to grow. The patent for the original tocilizumab injection has expired but no biosimilar drug has been approved in China. Currently, five pharmaceutical companies are carrying out relevant clinical trials. After Tocilizumab biosimilars are approved in the market, its manufacturers will gradually increase, the market will continue to grow and the price will decline. These situations will lead to an increase in Tocilizumab sales value and sales volume. In addition, Tocilizumab has been approved for 5 indications in other countries and China has approved 3 indications, so the number of approved indications in China has upside potential. It can be predicted that with the increase of indications, its sales will continue to grow with the expansion of the market in the future.

Topics Covered:
-The impact of COVID-19 on China’s Tocilizumab market
– Sales value of China’s Tocilizumab 2016-2020
– Competitive landscape of China’s Tocilizumab market
– Prices of Tocilizumab in China
– Prices of Tocilizumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Tocilizumab market
– Prospect of China’s Tocilizumab market from 2021 to 2025

The post Investigation Report on China’s Tocilizumab Market 2021-2025 first appeared on CRI Report.

Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-α) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis.

Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. By 2020, Janssen Biologics BV is the only manufacturer in the Chinese Infliximab market.

According to CRI’s market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price.

After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.86% in 2020 and reached CNY213.7 million. The CAGR for Infliximab is approximately 14.65% from 2016 to 2020.

CRI analyzes that the sales of Infliximab will keep a growth trend from 2021 to 2025 due to price reduction. After the patent for Infliximab expired, more biosimilar drugs have appeared in the market.

In China, three companies have already submitted applications for Infliximab in 2019 and 2020. Therefore, in the next few years, the market share for Janssen Biologics BV will gradually shrink. At the same time, with the launch of biosimilar drugs, the price will be further reduced. The price adjustment will reduce the burden on patients, thereby increasing the use and sales of Infliximab.

Topics Covered:
-The impact of COVID-19 on China’s Infliximab market
– Sales value of China’s Infliximab 2016-2020
– Competitive landscape of China’s Infliximab market
– Prices of Infliximab in China
– Prices of Infliximab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Infliximab market
– Prospect of China’s Infliximab market from 2021 to 2025

Investigation Report on China’s Infliximab Market, 2018-2022

The post Investigation Report on China’s Infliximab Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, after Ustekinumab entered the Chinese market, the sales increased from CNY0.6 million in 2019 to CNY 2.25 million in 2020. The annual growth rate is 274%

CRI analyzes that the sales of Ustekinumab will continue to increase in the next five years due to market expansion. After Ustekinumab was approved for its first indication in China in 2017, its second indication was approved in March 2020, which is used to treat moderate to severe active Crohn’s disease. With the approval of the new indication, sales will increase accordingly. Besides, Ustekinumab had four approved indications globally, which means the number of approved indications has the potential to expand in China, so the sales will keep increasing. On the other hand, the relatively high price for Ustekinumab results in suboptimal sales in China. Since Ustekinumab has only been in the Chinese market for a short period, Janssen is not enthusiastic about the national medical insurance negotiation. However, with the emergence of domestic biosimilar drugs in the future, the price for Ustekinumab is expected to decrease and the market will be further expanded.

Topics Covered:
-The impact of COVID-19 on China’s Ustekinumab market
– Sales value and volume of China’s Ustekinumab 2016-2020
– Competitive landscape of China’s Ustekinumab market
– Prices of Ustekinumab in China
– Prices of Ustekinumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Ustekinumab market
– Prospect of China’s Ustekinumab market from 2021 to 2025

The post Investigation Report on China’s Ustekinumab Market 2021-2025 first appeared on CRI Report.

Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1, mainly used to treat non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, advanced renal cell carcinoma, and head and neck squamous cell carcinoma.

Nivolumab was first developed by Medarex and Ono Pharmaceuticals. In 2009, Bristol-Myers Squibb acquired these two companies and obtained the patent for Nivolumab. Nivolumab was launched in China in 2018. By 2020, Bristol-Myers Squibb Pharma EEIG is the only manufacturer in the Chinese Nivolumab market.

According to CRI’s market research, after Nivolumab entered the Chinese market, the sales value of Nivolumab in China increased from CNY9.9 million in 2018 to CNY 43.1 million in 2020. The growth rate in 2020 was 52.2%, which slowed down due to the COVID-19 epidemic. The CAGR of Nivolumab’s sales values in China is 108.7 in 2018 to 2020%.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Nivolumab will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to market expansion. Currently, Nivolumab has three approved indications, including non-small cell lung cancer, head and neck squamous cell carcinoma, and gastric adenocarcinoma and gastroesophageal junction cancer.

Its fourth indication application is at the approval stage. As the number of approved indications increases, the sales will continue to grow. On the other hand, the usage rate of Nivolumab was lower than that of other PD-1 products that have been included in the national medical insurance catalog. If the medical insurance negotiation for Nivolumab succeeds, the price adjustment can reduce the burden on patients, which will increase its usage rate.

Topics Covered:
-The impact of COVID-19 on China’s Nivolumab market
– Sales value and volume of China’s Nivolumab 2016-2020
– Competitive landscape of China’s Nivolumab market
– Prices of Nivolumab in China
– Prices of Nivolumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Nivolumab market
– Prospect of China’s Nivolumab market from 2021 to 2025

The post Investigation Report on China’s Nivolumab Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales revenue of Rituximab in the Chinese market in 2016-2019 has an increase trend. The sales revenue of Rituximab in China increases from CNY943 million in 2016 to CNY1.42 billion in 2019. The sales value of Rituximab in China was approximately CNY1.3 billion in 2020. It decreased 8.4% Year on Year. The reason for the sales decline is that the COVID-19 epidemic has impacted the hospitals’ overall operation. The CAGR of sales value of Rituximab in China is 8.4% in 2016 to 2020.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Rituximab will have a recovery growth from 2021 to 2025. In addition, the sales will also increase due to the market expansion. Compared to indications approved in some developed countries, Rituximab has fewer indications being approved in China. The only two approved indications are non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Thus, the possibility of increase number of indications may bring new target patients for Rituximab. Besides, with the emergence of biosimilar drugs, Roche was no longer the monopoly in the Chinese Rituximab market. As a result, the price of Rituximab will be more affordable in the future, which will lead to an increase in sales volume.

Topics Covered:
-The impact of COVID-19 on China’s Rituximab market
– Sales value and volume of China’s Rituximab 2016-2020
– Competitive landscape of China’s Rituximab market
– Prices of Rituximab in China
– Prices of Rituximab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Rituximab market
– Prospect of China’s Rituximab market from 2021 to 2025

The post Investigation Report on China’s Rituximab Market 2021-2025 first appeared on CRI Report.